LILRB4 and acute myeloid leukemia: Interestingly, applying powerful cytotoxicity to AML cells in vitro, decrement of xenograft model tumor burden in vivo, and reduction of off-tumor toxicity by sparing normal progenitors and HSPCs were found as results of using LILRB4-CAR T cell [102].